Rosiglitazone decreases albuminuria in type 2 diabetic patients

Y. Miyazaki, Eugenio Cersosimo, Curtis L Triplitt, Ralph A Defronzo

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

Thiazolidinediones are insulin-sensitizing compounds that reduce plasma glucose and improve the lipid profile of type 2 diabetic patients. We determined the effect of rosiglitazone in 15 type 2 diabetic patients and compared these results to 14 randomly assigned placebo patients. After 3 months, the urinary albumin to creatinine ratio was significantly decreased, while the glucose metabolic clearance rate, during insulin clamp, was significantly increased by rosiglitazone compared to the placebo group. Fasting free fatty acid and tumor necrosis factor-α (TNF-α) levels were significantly decreased, while the adiponectin concentration was significantly increased by rosiglitazone treatment. The percentage decrease in albuminuria correlated with the decrease in fasting plasma glucose, free fatty acids TNF-α and the increase in fat mass, plasma adiponectin, and glucose metabolic clearance rate. Stepwise linear regression analysis showed the decrease in TNF-α and the increase in adiponectin were independently associated with decreased albuminuria. Our study indicates that thiazolidinediones may be useful to prevent nephropathy in type 2 diabetic patients.

Original languageEnglish (US)
Pages (from-to)1367-1373
Number of pages7
JournalKidney International
Volume72
Issue number11
DOIs
StatePublished - Dec 2007

Fingerprint

rosiglitazone
Albuminuria
Adiponectin
Metabolic Clearance Rate
Glucose
Thiazolidinediones
Tumor Necrosis Factor-alpha
Nonesterified Fatty Acids
Fasting
Placebos
Insulin
Albumins
Linear Models
Creatinine
Fats
Regression Analysis
Lipids

Keywords

  • Adipocytokines
  • Albuminuria
  • Insulin resistance
  • Thiazolidinediones
  • Type 2 diabetes

ASJC Scopus subject areas

  • Nephrology

Cite this

Rosiglitazone decreases albuminuria in type 2 diabetic patients. / Miyazaki, Y.; Cersosimo, Eugenio; Triplitt, Curtis L; Defronzo, Ralph A.

In: Kidney International, Vol. 72, No. 11, 12.2007, p. 1367-1373.

Research output: Contribution to journalArticle

Miyazaki, Y. ; Cersosimo, Eugenio ; Triplitt, Curtis L ; Defronzo, Ralph A. / Rosiglitazone decreases albuminuria in type 2 diabetic patients. In: Kidney International. 2007 ; Vol. 72, No. 11. pp. 1367-1373.
@article{72edfc57d9d249d3997d577111124cfa,
title = "Rosiglitazone decreases albuminuria in type 2 diabetic patients",
abstract = "Thiazolidinediones are insulin-sensitizing compounds that reduce plasma glucose and improve the lipid profile of type 2 diabetic patients. We determined the effect of rosiglitazone in 15 type 2 diabetic patients and compared these results to 14 randomly assigned placebo patients. After 3 months, the urinary albumin to creatinine ratio was significantly decreased, while the glucose metabolic clearance rate, during insulin clamp, was significantly increased by rosiglitazone compared to the placebo group. Fasting free fatty acid and tumor necrosis factor-α (TNF-α) levels were significantly decreased, while the adiponectin concentration was significantly increased by rosiglitazone treatment. The percentage decrease in albuminuria correlated with the decrease in fasting plasma glucose, free fatty acids TNF-α and the increase in fat mass, plasma adiponectin, and glucose metabolic clearance rate. Stepwise linear regression analysis showed the decrease in TNF-α and the increase in adiponectin were independently associated with decreased albuminuria. Our study indicates that thiazolidinediones may be useful to prevent nephropathy in type 2 diabetic patients.",
keywords = "Adipocytokines, Albuminuria, Insulin resistance, Thiazolidinediones, Type 2 diabetes",
author = "Y. Miyazaki and Eugenio Cersosimo and Triplitt, {Curtis L} and Defronzo, {Ralph A}",
year = "2007",
month = "12",
doi = "10.1038/sj.ki.5002516",
language = "English (US)",
volume = "72",
pages = "1367--1373",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Rosiglitazone decreases albuminuria in type 2 diabetic patients

AU - Miyazaki, Y.

AU - Cersosimo, Eugenio

AU - Triplitt, Curtis L

AU - Defronzo, Ralph A

PY - 2007/12

Y1 - 2007/12

N2 - Thiazolidinediones are insulin-sensitizing compounds that reduce plasma glucose and improve the lipid profile of type 2 diabetic patients. We determined the effect of rosiglitazone in 15 type 2 diabetic patients and compared these results to 14 randomly assigned placebo patients. After 3 months, the urinary albumin to creatinine ratio was significantly decreased, while the glucose metabolic clearance rate, during insulin clamp, was significantly increased by rosiglitazone compared to the placebo group. Fasting free fatty acid and tumor necrosis factor-α (TNF-α) levels were significantly decreased, while the adiponectin concentration was significantly increased by rosiglitazone treatment. The percentage decrease in albuminuria correlated with the decrease in fasting plasma glucose, free fatty acids TNF-α and the increase in fat mass, plasma adiponectin, and glucose metabolic clearance rate. Stepwise linear regression analysis showed the decrease in TNF-α and the increase in adiponectin were independently associated with decreased albuminuria. Our study indicates that thiazolidinediones may be useful to prevent nephropathy in type 2 diabetic patients.

AB - Thiazolidinediones are insulin-sensitizing compounds that reduce plasma glucose and improve the lipid profile of type 2 diabetic patients. We determined the effect of rosiglitazone in 15 type 2 diabetic patients and compared these results to 14 randomly assigned placebo patients. After 3 months, the urinary albumin to creatinine ratio was significantly decreased, while the glucose metabolic clearance rate, during insulin clamp, was significantly increased by rosiglitazone compared to the placebo group. Fasting free fatty acid and tumor necrosis factor-α (TNF-α) levels were significantly decreased, while the adiponectin concentration was significantly increased by rosiglitazone treatment. The percentage decrease in albuminuria correlated with the decrease in fasting plasma glucose, free fatty acids TNF-α and the increase in fat mass, plasma adiponectin, and glucose metabolic clearance rate. Stepwise linear regression analysis showed the decrease in TNF-α and the increase in adiponectin were independently associated with decreased albuminuria. Our study indicates that thiazolidinediones may be useful to prevent nephropathy in type 2 diabetic patients.

KW - Adipocytokines

KW - Albuminuria

KW - Insulin resistance

KW - Thiazolidinediones

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=36249006990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36249006990&partnerID=8YFLogxK

U2 - 10.1038/sj.ki.5002516

DO - 10.1038/sj.ki.5002516

M3 - Article

C2 - 17805239

AN - SCOPUS:36249006990

VL - 72

SP - 1367

EP - 1373

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 11

ER -